Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Synthetic biology

- PMLiVE

Nestlé and Seres announce new partnership for C.diff microbiome therapeutic

The companies will jointly commercialise Seres’ investigational oral microbiome therapeutic in the US and Canada

- PMLiVE

eureKARE to use $60m financing to bolster next-generation European biotech companies

New company is focused on financing biotech companies and new ventures in Europe working on the microbiome and synthetic biology

Can Science Save Us?

Dr. Mark Poznansky, Founder/Blogger at Saved By Science explores the importance of improving health literacy among the general population, along with the scientific and technological innovations that he believes could help save...

Impetus Digital

- PMLiVE

Seres’ microbiome-based therapy hits the mark in phase 3

Drug reduced C.difficile infection recurrence

- PMLiVE

European biotech: a new generation of leaders emerges

Three companies that are on the rise in biotech

- PMLiVE

Finch Therapeutics bags $53m for microbiome therapies

In race to be first-to-market in C diff

- PMLiVE

Building Europe’s next breakthrough biotechs

Start Codon's Daniel Rooke on fostering biotech success in Cambridge, UK

- PMLiVE

Novartis and J&J back latest €400m Medicxi biopharma fund

Growing appetite from European investors to back early-stage biotechs

- PMLiVE

Illumina sets up first ex-US accelerator site in Cambridge

Boost for UK's golden triangle biotech region

- PMLiVE

Gilead strikes $5.1bn deal to bolster ties with Galapagos

Big boost for Belgian biotech, without a buy-out

- PMLiVE

BioNTech raises €290m for mRNA cancer vaccine platform

Funds will help lead melanoma candidate progress

- PMLiVE

Citryll snares €15m backing for its autoimmune disease NETs

New approach to tackling diseases such as lupus, RA

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links